Paper41844740
CHD1L promotes testicular cancer progression through epigenetic activation of the CXCR6/PI3K/AKT pathway.
Zhao Y and 5 others. Sci Rep, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. CHD1L promotes testicular cancer progression through epigenetic activation of the CXCR6/PI3K/AKT pathway. Papers, record 41844740. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41844740
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- CHD1L promotes testicular cancer progression through epigenetic activation of the CXCR6/PI3K/AKT pathway.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Testicular Neoplasms | Major topic |
| Proto-Oncogene Proteins c-akt | Major topic |
| Phosphatidylinositol 3-Kinases | Major topic |
| Epigenesis, Genetic | Major topic |
| DNA Helicases | Major topic |
| DNA-Binding Proteins | Major topic |
| Receptors, CXCR6 | Major topic |
| Male | |
| Humans | |
| Animals | |
| Signal Transduction | |
| Mice | |
| Gene Expression Regulation, Neoplastic | |
| Disease Progression | |
| Cell Line, Tumor | |
| Cell Proliferation | |
| Cell Movement |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82171611, 81971376 | National Natural Science Foundation of China-China Academy of General Technology Joint Fund for Basic Research | PubMed | ||
| 2022YFC2804300 | National Key Research and Development Program of China | PubMed | ||
| 21ZR14389001 | Shanghai Science and Technology Commission Research Project | PubMed |
Source PubMed
References40
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25371726 | Chromodomain helicase/ATPase DNA binding protein 1-like protein expression predicts poor prognosis in nasopharyngeal carcinoma. | Exp Ther Med | 2014 | https://conductscience.org/library/papers/25371726 | PubMed |
| 2 | 34298782 | CXCR6-CXCL16 Axis Promotes Breast Cancer by Inducing Oncogenic Signaling. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34298782 | PubMed |
| 3 | 33800554 | The Role of CXCL16 in the Pathogenesis of Cancer and Other Diseases. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/33800554 | PubMed |
| 4 | 30577487 | The Role of DNA/Histone Modifying Enzymes and Chromatin Remodeling Complexes in Testicular Germ Cell Tumors. | Cancers (Basel) | 2018 | https://conductscience.org/library/papers/30577487 | PubMed |
| 5 | 24242335 | Genetic and epigenetic changes in fibrosis-associated hepatocarcinogenesis in mice. | Int J Cancer | 2014 | https://conductscience.org/library/papers/24242335 | PubMed |
| 6 | 33538338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
| 7 | 21816936 | CXCL16 recruits bone marrow-derived fibroblast precursors in renal fibrosis. | J Am Soc Nephrol | 2011 | https://conductscience.org/library/papers/21816936 | PubMed |
| 8 | 32164473 | Further insights into testicular germ cell tumor oncogenesis: potential therapeutic targets. | Expert Rev Anticancer Ther | 2020 | https://conductscience.org/library/papers/32164473 | PubMed |
| 9 | 20335658 | CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients. | J Clin Invest | 2010 | https://conductscience.org/library/papers/20335658 | PubMed |
| 10 | 20043168 | Deregulation of EZH2 expression in human spermatogenic disorders and testicular germ cell tumors. | World J Urol | 2010 | https://conductscience.org/library/papers/20043168 | PubMed |
| 11 | 33729863 | Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. | J Clin Oncol | 2021 | https://conductscience.org/library/papers/33729863 | PubMed |
| 12 | 18293410 | Overexpression of CXCL16 and its receptor CXCR6/Bonzo promotes growth of human schwannomas. | Glia | 2008 | https://conductscience.org/library/papers/18293410 | PubMed |
| 13 | 30060750 | Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1β/VEGFA signalling. | Mol Cancer | 2018 | https://conductscience.org/library/papers/30060750 | PubMed |
| 14 | 30850015 | Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming. | Clin Epigenetics | 2019 | https://conductscience.org/library/papers/30850015 | PubMed |
| 15 | 26559672 | CXCL16 signaling mediated macrophage effects on tumor invasion of papillary thyroid carcinoma. | Endocr Relat Cancer | 2016 | https://conductscience.org/library/papers/26559672 | PubMed |
| 16 | 31324498 | International Trends in the Incidence of Testicular Cancer: Lessons from 35 Years and 41 Countries. | Eur Urol | 2019 | https://conductscience.org/library/papers/31324498 | PubMed |
| 17 | 19576697 | First-line chemotherapy of non-seminomatous germ cell tumors(NSGCTs). | Cancer Treat Rev | 2009 | https://conductscience.org/library/papers/19576697 | PubMed |
| 18 | 23746766 | CHD1L promotes tumor progression and predicts survival in colorectal carcinoma. | J Surg Res | 2013 | https://conductscience.org/library/papers/23746766 | PubMed |
| 19 | 32593915 | Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities. | Cancer Treat Rev | 2020 | https://conductscience.org/library/papers/32593915 | PubMed |
| 20 | 34667158 | Histone demethylase KDM4D inhibition suppresses renal cancer progression and angiogenesis through JAG1 signaling. | Cell Death Discov | 2021 | https://conductscience.org/library/papers/34667158 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42353640 | In Vitro Evaluation of Combination Therapy with Doxorubicin and Quercetin for Uveal Melanoma. | Curr Issues Mol Biol | 2026 | https://conductscience.org/library/papers/42353640 |
Source PubMed
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| CHD1L | 9557 | PubTator's text mining | https://conductscience.org/library/genes/9557 | NCBI Gene |
| CXCR6 | 10663 | PubTator's text mining | https://conductscience.org/library/genes/10663 | NCBI Gene |
| PIK3CB | 5291 | PubTator's text mining | https://conductscience.org/library/genes/5291 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41844740
GET https://conductscience.org/api/papers/v1/41844740/references?page=2